Global Cancer Technology Inc
Global Cancer Technology is a non-revenue biopharma company dedicated to developing innovative treatments for cancers, particularly glioblastoma. They focus on a small molecule PI3K inhibitor capable of crossing the blood-brain barrier, showing promise in preclinical studies. Their mission is to improve cancer treatment outcomes through novel drug delivery technologies and targeted therapies.
Industries
Nr. of Employees
small (1-50)
Patents
Tri-substituted aryl and heteroaryl derivatives as modulators of PI3-kinase and autophagy pathways
US-12049462-B2
View DetailsTri-substituted aryl and heteroaryl derivatives as modulators of PI3-kinase and autophagy pathways
US-11492348-B2
View Details
Tri-substituted aryl and heteroaryl derivatives as modulators of PI3-kinase and autophagy pathways
US-12049462-B2
View DetailsTri-substituted aryl and heteroaryl derivatives as modulators of PI3-kinase and autophagy pathways
US-11492348-B2
View DetailsProducts
Dual PI3K/mTOR BBB‑penetrant small‑molecule inhibitor (preclinical)
A small‑molecule dual inhibitor designed to target PI3K and mTOR signaling, optimized for blood–brain barrier penetration and shown in preclinical studies to induce tumor growth arrest and increase radiosensitivity and immune recognition.
VPS34 inhibitor series (patent‑pending)
Morpholine‑derived inhibitors of VPS34 (autophagy pathway) developed as part of autophagy‑targeting strategies; listed as patent pending.
Irradiation‑activated nano‑vehicle drug delivery platform
A nano‑carrier platform incorporating scintillating nanocrystals intended to carry a pro‑drug and enable localized activation via low‑dose or wide‑field irradiation to limit off‑target toxicity.
Dual PI3K/mTOR BBB‑penetrant small‑molecule inhibitor (preclinical)
A small‑molecule dual inhibitor designed to target PI3K and mTOR signaling, optimized for blood–brain barrier penetration and shown in preclinical studies to induce tumor growth arrest and increase radiosensitivity and immune recognition.
VPS34 inhibitor series (patent‑pending)
Morpholine‑derived inhibitors of VPS34 (autophagy pathway) developed as part of autophagy‑targeting strategies; listed as patent pending.
Irradiation‑activated nano‑vehicle drug delivery platform
A nano‑carrier platform incorporating scintillating nanocrystals intended to carry a pro‑drug and enable localized activation via low‑dose or wide‑field irradiation to limit off‑target toxicity.
Services
Licensing and management of patent rights for small-molecule modulators, delivery technologies, and combination uses.
Licensing and management of patent rights for small-molecule modulators, delivery technologies, and combination uses.
Expertise Areas
- Glioblastoma and CNS oncology drug development
- Small‑molecule PI3K/mTOR therapeutic development
- Autophagy‑targeted therapeutic approaches
- VPS34 inhibitor development
Key Technologies
- PI3K/mTOR dual inhibition
- Autophagy pathway modulation
- VPS34 inhibition
- Blood–brain barrier‑penetrant small molecules